$VYNE
VYNE Therapeutics Inc. Stock $vyne

$vyne Overview Financials Valuation SEC Filings Company Website

2021 Q2 Form 10-Q Financial Statement

#000156604421000034 Filed on August 12, 2021

Income Statement

Concept	2021 Q2	2020 Q2	2020 Q1
Revenue	$295.0K	$11.69M	$1.750M
YoY Change	-97.48%		468.18%
Cost Of Revenue	$795.0K	$178.9M	$41.64M
YoY Change	-99.56%	823.94%	157.16%
Gross Profit	-$500.0K	-$167.2M	-$39.89M
YoY Change	-99.7%	763.56%	151.13%
Gross Profit Margin	-169.49%	-1430.33%	-2279.37%
Selling, General & Admin	$4.789M	$26.46M	$25.42M
YoY Change	-81.9%	288.93%	375.94%
% of Gross Profit
Research & Development	$5.048M	$13.12M	$15.95M
YoY Change	-61.52%	4.48%	0.19%
% of Gross Profit
Depreciation & Amortization	$25.00K	$100.0K	$93.00K
YoY Change	-75.0%	25.0%	16.25%
% of Gross Profit
Operating Expenses	$9.837M	$39.58M	$41.37M
YoY Change	-75.15%	129.89%	110.32%
Operating Profit	-$9.542M	-$167.2M	-$39.89M
YoY Change	-94.29%	763.56%	151.13%
Interest Expense	$1.074M	$1.070M	$1.067M
YoY Change	0.37%	44.79%	34.05%
% of Operating Profit
Other Income/Expense, Net	-$69.00K	$548.0K	$723.0K
YoY Change	-112.59%	-25.85%	-9.17%
Pretax Income	-$10.69M	-$167.7M	-$40.23M
YoY Change	-93.63%	782.95%	161.59%
Income Tax	$0.00	-$259.0K	$0.00
% Of Pretax Income
Net Earnings	-$19.92M	-$167.4M	-$40.23M
YoY Change	-88.1%	781.59%	113.18%
Net Earnings / Revenue	-6753.9%	-1432.58%	-2299.03%
Basic Earnings Per Share	-$0.39	-$4.83
Diluted Earnings Per Share	-$0.39	-$4.83	-$3.785M
COMMON SHARES
Basic Shares Outstanding	51.41M shares	34.66M shares	24.44M
Diluted Shares Outstanding	51.41M shares	34.66M shares

Balance Sheet

Concept	2021 Q2	2020 Q2	2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$103.4M	$99.12M	$57.60M
YoY Change	4.32%	-9.4%	-52.59%
Cash & Equivalents	$103.4M	$96.51M	$57.60M
Short-Term Investments		$2.609M	$0.00
Other Short-Term Assets	$5.873M	$6.600M	$29.30M
YoY Change	-11.02%	78.38%	691.89%
Inventory	$8.279M	$5.801M	$3.200M
Prepaid Expenses
Receivables	$10.87M	$6.407M	$8.300M
Other Receivables	$0.00	$4.000M	$0.00
Total Short-Term Assets	$128.4M	$119.3M	$98.40M
YoY Change	7.66%	5.45%	-21.42%
LONG-TERM ASSETS
Property, Plant & Equipment	$501.0K	$2.811M	$4.600M
YoY Change	-82.18%	2096.09%	3116.78%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$3.831M	$6.200M	$53.50M
YoY Change	-38.21%	6100.0%	26650.0%
Total Long-Term Assets	$5.557M	$11.55M	$62.10M
YoY Change	-51.9%	819.01%	5660.67%
TOTAL ASSETS
Total Short-Term Assets	$128.4M	$119.3M	$98.40M
Total Long-Term Assets	$5.557M	$11.55M	$62.10M
Total Assets	$134.0M	$130.8M	$160.5M
YoY Change	2.4%	14.39%	27.08%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$10.08M	$10.00M	$14.10M
YoY Change	0.8%	112.59%	271.05%
Accrued Expenses	$10.15M	$8.812M	$13.50M
YoY Change	15.14%	35.84%	110.94%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$33.38M
YoY Change
Total Short-Term Liabilities	$57.62M	$24.23M	$56.60M
YoY Change	137.78%	103.53%	433.96%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$32.92M	$32.80M
YoY Change	-100.0%
Other Long-Term Liabilities	$1.470M	$2.200M	$1.600M
YoY Change	-33.18%	633.33%
Total Long-Term Liabilities	$0.00	$35.08M	$34.40M
YoY Change	-100.0%	11594.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$57.62M	$24.23M	$56.60M
Total Long-Term Liabilities	$0.00	$35.08M	$34.40M
Total Liabilities	$59.09M	$59.31M	$91.00M
YoY Change	-0.38%	385.9%	756.31%
SHAREHOLDERS EQUITY
Retained Earnings	-$606.7M	-$518.3M
YoY Change	17.06%	255.03%
Common Stock	$5.000K	$17.00K
YoY Change	-70.59%	-99.99%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$74.89M	$71.53M	$69.54M
YoY Change
Total Liabilities & Shareholders Equity	$134.0M	$130.8M	$160.5M
YoY Change	2.4%	14.39%	27.12%

Cashflow Statement

Concept	2021 Q2	2020 Q2	2020 Q1
OPERATING ACTIVITIES
Net Income	-$19.92M	-$167.4M	-$40.23M
YoY Change	-88.1%	781.59%	113.18%
Depreciation, Depletion And Amortization	$25.00K	$100.0K	$93.00K
YoY Change	-75.0%	25.0%	16.25%
Cash From Operating Activities	-$16.26M	-$35.86M	-$52.21M
YoY Change	-54.66%	181.92%	213.77%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	-$70.00K	$42.00K
YoY Change	-100.0%	-77.42%	-130.0%
Acquisitions
YoY Change
Other Investing Activities	$1.027M	$21.20M	$66.02M
YoY Change	-95.16%	-35.93%	737.82%
Cash From Investing Activities	$1.027M	$21.13M	$65.98M
YoY Change	-95.14%	-35.52%	752.45%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-126.0K	53.61M	$140.0K
YoY Change	-100.24%		600.0%
NET CHANGE
Cash From Operating Activities	-16.26M	-35.86M	-$52.21M
Cash From Investing Activities	1.027M	21.13M	$65.98M
Cash From Financing Activities	-126.0K	53.61M	$140.0K
Net Change In Cash	-15.36M	38.88M	$13.91M
YoY Change	-139.5%	93.92%	-256.63%
FREE CASH FLOW
Cash From Operating Activities	-$16.26M	-$35.86M	-$52.21M
Capital Expenditures	$0.00	-$70.00K	$42.00K
Free Cash Flow	-$16.26M	-$35.79M	-$52.25M
YoY Change	-54.57%	188.4%	216.68%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Central Index Key EntityCentralIndexKey	0001566044
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Amendment Flag AmendmentFlag	false
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021Q1	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.25
CY2021Q1	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.25
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2021-06-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-38356
	dei	Entity Registrant Name EntityRegistrantName	VYNE THERAPEUTICS INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	45-3757789
	dei	Entity Address Address Line1 EntityAddressAddressLine1	520 U.S. Highway 22, Suite 204
	dei	Entity Address City Or Town EntityAddressCityOrTown	Bridgewater
	dei	Entity Address State Or Province EntityAddressStateOrProvince	NJ
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	08807
	dei	City Area Code CityAreaCode	800
	dei	Local Phone Number LocalPhoneNumber	775-7936
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001
	dei	Trading Symbol TradingSymbol	VYNE
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Shell Company EntityShellCompany	false
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	true
CY2021Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	51511845	shares
CY2021Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	103406000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	57563000	USD
CY2021Q2	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	605000	USD
CY2020Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	855000	USD
CY2021Q2	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	0	USD
CY2020Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	1027000	USD
CY2021Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	10868000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	15819000	USD
CY2021Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5268000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4591000	USD
CY2021Q2	us-gaap	Inventory Net InventoryNet	8279000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	7404000	USD
CY2021Q2	us-gaap	Assets Current AssetsCurrent	128426000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	87259000	USD
CY2021Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	501000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	555000	USD
CY2021Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1225000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1583000	USD
CY2021Q2	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	3831000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	4345000	USD
CY2021Q2	us-gaap	Assets Assets	133983000	USD
CY2020Q4	us-gaap	Assets Assets	93742000	USD
CY2021Q2	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	10080000	USD
CY2020Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	4780000	USD
CY2021Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	10146000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	11452000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	757000	USD
CY2021Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	33375000	USD
CY2020Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	0	USD
CY2021Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3481000	USD
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4360000	USD
CY2021Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	434000	USD
CY2021Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	104000	USD
CY2020Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	104000	USD
CY2021Q2	us-gaap	Liabilities Current LiabilitiesCurrent	57620000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	21453000	USD
CY2021Q2	us-gaap	Supplemental Unemployment Benefits Severance Benefits SupplementalUnemploymentBenefitsSeveranceBenefits	206000	USD
CY2020Q4	us-gaap	Supplemental Unemployment Benefits Severance Benefits SupplementalUnemploymentBenefitsSeveranceBenefits	312000	USD
CY2021Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	812000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	853000	USD
CY2021Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	0	USD
CY2020Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	33174000	USD
CY2021Q2	us-gaap	Other Liabilities OtherLiabilities	452000	USD
CY2020Q4	us-gaap	Other Liabilities OtherLiabilities	457000	USD
CY2021Q2	us-gaap	Liabilities Liabilities	59090000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	56249000	USD
CY2021Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies	0	USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies	0	USD
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2021Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2021Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2021Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	51511845	shares
CY2021Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	51511845	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	43205221	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	43205221	shares
CY2021Q2	us-gaap	Common Stock Value CommonStockValue	5000	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	4000	USD
CY2021Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	681558000	USD
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	603685000	USD
CY2021Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-606670000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-566196000	USD
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	74893000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	37493000	USD
CY2021Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	133983000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	93742000	USD
CY2021Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	4258000	USD
CY2020Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	11688000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	8377000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	13438000	USD
CY2021Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	795000	USD
CY2020Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	216000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1396000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	487000	USD
CY2021Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6409000	USD
CY2020Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	13119000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	12742000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	29072000	USD
CY2021Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	15835000	USD
CY2020Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	26459000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	32451000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	51874000	USD
CY2021Q2	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	0	USD
CY2020Q2	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	54345000	USD
	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	0	USD
	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	54345000	USD
CY2021Q2	vyne	Contingent Stock Consideration Remeasurement Gain Loss ContingentStockConsiderationRemeasurementGainLoss	0	USD
CY2020Q2	vyne	Contingent Stock Consideration Remeasurement Gain Loss ContingentStockConsiderationRemeasurementGainLoss	-84726000	USD
	vyne	Contingent Stock Consideration Remeasurement Gain Loss ContingentStockConsiderationRemeasurementGainLoss	0	USD
	vyne	Contingent Stock Consideration Remeasurement Gain Loss ContingentStockConsiderationRemeasurementGainLoss	-84726000	USD
CY2021Q2	us-gaap	Costs And Expenses CostsAndExpenses	22244000	USD
CY2020Q2	us-gaap	Costs And Expenses CostsAndExpenses	178649000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	45193000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	220017000	USD
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-18781000	USD
CY2020Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-167177000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-38212000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-207066000	USD
CY2021Q2	us-gaap	Interest Expense InterestExpense	1074000	USD
CY2020Q2	us-gaap	Interest Expense InterestExpense	1070000	USD
	us-gaap	Interest Expense InterestExpense	2136000	USD
	us-gaap	Interest Expense InterestExpense	2137000	USD
CY2021Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-69000	USD
CY2020Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	548000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-126000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1271000	USD
CY2021Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-19924000	USD
CY2020Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-167699000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-40474000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-207932000	USD
CY2021Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2020Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-259000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-259000	USD
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-19924000	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-167440000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-40474000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-207673000	USD
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.39
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.39
CY2020Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-4.83
CY2020Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-4.83
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.81
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.81
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-9.17
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-9.17
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	51411000	shares
CY2021Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	51411000	shares
CY2020Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	34663000	shares
CY2020Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	34663000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	50162000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	50162000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	22656000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	22656000	shares
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-19924000	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-167440000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-40474000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-207673000	USD
CY2021Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	0	USD
CY2020Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	43000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	0	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-1000	USD
CY2021Q2	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	0	USD
CY2020Q2	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	-3000	USD
	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	0	USD
	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	-4000	USD
CY2021Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	0	USD
CY2020Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	40000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	0	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-5000	USD
CY2021Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-19924000	USD
CY2020Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-167400000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-40474000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-207678000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	17575000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-207678000	USD
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	260000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions	12527000	USD
	vyne	Deemed Dividend To Warrants Holders Due To Warrant Modification DeemedDividendToWarrantsHoldersDueToWarrantModification	0	USD
	vyne	Share Based Payment Modification Of Terms Incremental Compensation Modification Of Terms Incremental Compensation Cost Reclassified Adjustment ShareBasedPaymentModificationOfTermsIncrementalCompensationModificationOfTermsIncrementalCompensationCostReclassifiedAdjustment	975000	USD
CY2020Q2	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	3903000	USD
	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	196170000	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	71528000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	37493000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-40474000	USD
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	403000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions	4343000	USD
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	74893000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	69535000	USD
CY2020Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-167400000	USD
CY2020Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	-43000	USD
CY2020Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions	10768000	USD
CY2020Q2	vyne	Share Based Payment Modification Of Terms Incremental Compensation Modification Of Terms Incremental Compensation Cost Reclassified Adjustment ShareBasedPaymentModificationOfTermsIncrementalCompensationModificationOfTermsIncrementalCompensationCostReclassifiedAdjustment	-657000	USD
CY2020Q2	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	3903000	USD
CY2020Q2	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	104362000	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	71528000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	92901000	USD
CY2021Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-19924000	USD
CY2021Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	15000	USD
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions	1901000	USD
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	74893000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-40474000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-207673000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	55000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	187000	USD
	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	0	USD
	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	54345000	USD
	vyne	Contingent Stock Consideration Remeasurement Gain Loss ContingentStockConsiderationRemeasurementGainLoss	0	USD
	vyne	Contingent Stock Consideration Remeasurement Gain Loss ContingentStockConsiderationRemeasurementGainLoss	-84726000	USD
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	0	USD
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	142000	USD
	vyne	Increase Decrease In Employee Severance Liability Net Of Retirement Fund Profits IncreaseDecreaseInEmployeeSeveranceLiabilityNetOfRetirementFundProfits	-108000	USD
	vyne	Increase Decrease In Employee Severance Liability Net Of Retirement Fund Profits IncreaseDecreaseInEmployeeSeveranceLiabilityNetOfRetirementFundProfits	-21000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	4343000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	12527000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	150000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	833000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-4266000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	9807000	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-876000	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	6026000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	3259000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-10908000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	875000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	4445000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-28808000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-88070000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	113000	USD
	vyne	Proceeds From Business Merger ProceedsFromBusinessMerger	0	USD
	vyne	Proceeds From Business Merger ProceedsFromBusinessMerger	38641000	USD
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	1027000	USD
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	48577000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	1027000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	87105000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	73127000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	53646000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	247000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	100000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	73374000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	53746000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	45593000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	52781000	USD
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	0	USD
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	58418000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	44584000	USD
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	104011000	USD
CY2020Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	97366000	USD
CY2021Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	103406000	USD
CY2020Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	96511000	USD
CY2021Q2	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	605000	USD
CY2020Q2	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	855000	USD
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	104011000	USD
CY2020Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	97366000	USD
	us-gaap	Stock Issued1 StockIssued1	144000	USD
	us-gaap	Stock Issued1 StockIssued1	163000	USD
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	USD
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1120000	USD
	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	0	USD
	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	1120000	USD
	vyne	Interest Received InterestReceived	11000	USD
	vyne	Interest Received InterestReceived	298000	USD
	us-gaap	Interest Paid Net InterestPaidNet	1936000	USD
	us-gaap	Interest Paid Net InterestPaidNet	1946000	USD
	us-gaap	Noncash Or Part Noncash Acquisition Value Of Assets Acquired1 NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1	0	USD
CY2020Q2	vyne	Post Merger Parent Ownership By Pre Merger Subsidiary Shareholders PostMergerParentOwnershipByPreMergerSubsidiaryShareholders	0.82
CY2020Q2	vyne	Post Merger Parent Ownership By Pre Merger Parent Stockholders PostMergerParentOwnershipByPreMergerParentStockholders	0.18
	us-gaap	Use Of Estimates UseOfEstimates	Use of Estimates<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and reported amounts of income and expenses during the reporting periods. Significant items subject to such estimates and assumptions include accounting for business combinations, impairments of goodwill and intangible assets and revenue recognition. Actual results could differ from the Company’s estimates.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The COVID-19 pandemic and government measures taken in response to the pandemic have had a negative impact on the Company's operations. Access to healthcare providers has been limited, which has negatively impacted sales and the Company's ability to execute its commercial strategy with respect to AMZEEQ and ZILXI. The length of time and extent to which the COVID-19 pandemic will directly or indirectly impact the Company's business, results of operations and financial condition and liquidity will depend on future developments that are highly uncertain, subject to change and will continue to evolve with geographical re-openings, surges in cases, the development of new strains and the vaccination effort. In addition, the Company further assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company and the unknown future impacts of COVID-19 as of June 30, 2021 and through the date of this report. The accounting matters assessed included, but were not limited to, the Company’s allowance for doubtful accounts and credit losses, inventory and related reserves, impairments of long-lived assets and revenue recognition.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In 2020, the Company recorded impairments of goodwill and certain indefinite-lived intangible assets; however, these were unrelated to the impact of COVID-19 (See "Note 3 - Business Combination" for more information).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The </span></div>Company’s future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in material impacts to the Company’s consolidated financial statements in future reporting periods
	us-gaap	Noncash Or Part Noncash Acquisition Value Of Assets Acquired1 NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1	117270000	USD
	us-gaap	Noncash Or Part Noncash Acquisition Value Of Liabilities Assumed1 NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1	0	USD
	vyne	Non Cash Acquisition Of Business Cash Acquired NonCashAcquisitionOfBusinessCashAcquired	38641000	USD
	us-gaap	Noncash Or Part Noncash Acquisition Value Of Liabilities Assumed1 NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1	5827000	USD
	us-gaap	Noncash Or Part Noncash Acquisition Net Nonmonetary Assets Acquired Liabilities Assumed1 NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1	0	USD
	us-gaap	Noncash Or Part Noncash Acquisition Net Nonmonetary Assets Acquired Liabilities Assumed1 NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1	111443000	USD
	vyne	Non Cash Acquisition Of Business Cash Acquired NonCashAcquisitionOfBusinessCashAcquired	0	USD
	vyne	Non Cash Acquisition Of Business Net Assets After Cash Acquired NonCashAcquisitionOfBusinessNetAssetsAfterCashAcquired	0	USD
	vyne	Non Cash Acquisition Of Business Net Assets After Cash Acquired NonCashAcquisitionOfBusinessNetAssetsAfterCashAcquired	72802000	USD
	us-gaap	Nature Of Operations NatureOfOperations	NATURE OF OPERATIONS<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">VYNE Therapeutics Inc. ("VYNE" or the "Company") is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory diseases of high unmet medical need. The Company is a Delaware corporation, has its principal executive offices in Bridgewater, New Jersey and operates as one business segment. The Company currently has two commercial products, AMZEEQ® (minocycline) topical foam, 4%, and ZILXI® (minocycline) topical foam, 1.5%. As discussed below, the Company has initiated a process to explore a possible sale or license of its topical minocycline franchise. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Strategic Business Review</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in the second quarter of 2021, the Company conducted a review of its commercial and research and development portfolio to determine how to optimally deploy capital and drive shareholder value. During the course of this review, the Company carefully considered the revenues received from the commercialization of AMZEEQ and ZILXI and the associated costs to drive those revenues, the protracted negative impact of the COVID-19 pandemic over the past 18 months during the commercial launches of both AMZEEQ and ZILXI, the current payor landscape, as well as the costs to develop each of its pipeline products. During this process, the Company evaluated several strategic options including the acquisition of marketed assets, out-licensing its approved products outside of the United States, and possible partnering or co-development relationships with interested parties. Following its review, the Company has determined to initiate a process to explore a possible sale or license of its topical minocycline franchise, including AMZEEQ, ZILXI, FCD105 (the Company’s Phase 3 proprietary novel topical combination foam formulation of minocycline and adapalene for the treatment of moderate-to-severe acne vulgaris) and the underlying Molecule Stabilizing Technology platform. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By leveraging its drug development and clinical development capabilities and strong network of discovery and preclinical science partners, the Company will transition its strategic focus to develop therapies for the treatment of immuno-inflammatory diseases of high unmet medical need. The Company expects to continue to invest in FMX114 for the treatment of mild to moderate atopic dermatitis and anticipates the first patient in its Phase 2a proof-of-concept study will be enrolled in the third quarter of 2021. The Company expects results from this study by the end of 2021. In addition, on August 12, 2021, the Company announced a transaction with In4Derm Limited, a company incorporated and registered in Scotland (“In4Derm”). In4Derm is a spin-out of the University of Dundee’s School of Life Sciences which has discovered and is developing proprietary Bromodomain and Extra-Terminal Domain Inhibitors (“BETi”) for the treatment of immunology and oncology conditions. On April 30, 2021, the parties entered into an Evaluation and Option Agreement (the “Option Agreement”) pursuant to which In4Derm granted the Company an exclusive option to obtain exclusive worldwide rights to research, develop and commercialize products containing In4Derm’s BETi compounds, which are new chemical entities, in both topical (the “Topical BETi Option”) and oral (the “Oral BETi Option”) treatments in all fields for any disease, disorder or condition in humans. On August 6, 2021, the Company exercised the Topical BETi Option and the parties entered into a License Agreement granting the Company a worldwide, exclusive license that is sublicensable through multiple tiers to exploit certain of In4Derm’s BETi compounds identified to be suitable for topical administration in all fields. The Company paid a $1.0 million cash payment to In4Derm upon the execution of the Option Agreement and $0.5 million in connection with the exercise of the Topical BETi Option. Pursuant to the License Agreement, the Company has agreed to make cash payments to In4Derm upon the achievement of specified clinical development and regulatory approval milestones with respect to each licensed topical product in the U.S. of up to $15.75 million for all indications. In addition, the Company currently expects to exercise the Oral BETi Option following the selection of a lead candidate for the program. Upon exercise of the exclusive Oral BETi Option, the parties will sign a license agreement (the “Oral License Agreement”), and the Company will be required to pay In4Derm a $4.0 million cash payment. The Oral License Agreement will include cash payments of up to $43.75 million payable to In4Derm upon the achievement of specified clinical development and regulatory approval milestones with respect to each licensed oral product in the U.S. for all indications. The license agreements also provide for tiered royalty payments of up to 10% of net annual sales across licensed BETi products by the Company. In4Derm is entitled to additional milestones upon the achievement of regulatory approvals in certain jurisdictions outside the U.S. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The initial BETi candidates that the Company plans to develop are VYN201 and VYN202. VYN201 is a pan-bromodomain or pan-BD BET inhibitor.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is a first-in-class “soft” pan-BD BET inhibitor that is designed to mitigate systemic drug exposure and will be developed for topical applications. The Company intends to progress VYN201 into rare, neutrophilic, dermatological </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">indications where there is significant unmet need due to a lack of indicated treatment options. The Company plans to enter this program into the clinic in 2022 after the prerequisite non-clinical safety assessments have been completed.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The second candidate, VYN202, is an orally-delivered, first-in-class BET inhibitor that is highly selective for Bromodomain 2 ("BD2"). Recent research has suggested that the majority of pro-inflammatory signaling via BET protein action is via interactions with BD2. By selectively inhibiting BD2, the Company believes VYN202 could have a more targeted anti-inflammatory effect with an improved benefit/risk profile. The Company views VYN202 as having significant potential as a novel, oral treatment for major immuno-inflammatory indications. Following the exercise of the Oral BETi Option, the Company intends to commence a IND-enabling non-clinical safety program for VYN202 and enter the clinic in 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the Company transitions from a commercial organization to one focused on research and development, the Company intends to streamline operations by eliminating the vast majority of planned expenditures supporting its commercial operations. Furthermore, the Company intends to reduce its workforce by terminating approximately 70 employees, which the Company expects to be completed by December 31, 2021. The Company expects to incur a one-time charge in the range of approximately $1.5 million to $2.0 million, excluding non-cash charges, in connection with this restructuring plan, consisting primarily of employee termination costs, including severance and other benefits. This charge is expected to be incurred during the quarter ending September 30, 2021 with related cash payments expected to be substantially paid out by December 31, 2021.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reverse Merger</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 10, 2019, Menlo, Foamix Pharmaceuticals Ltd. (“Foamix”) and Giants Merger Subsidiary Ltd. (“Merger Sub”), a wholly-owned subsidiary of Menlo, entered into an Agreement and Plan of Merger (as amended by Amendment No. 1 to the Agreement and Plan of Merger, dated as of December 4, 2019, the “Merger Agreement”). Pursuant to the terms of the Merger Agreement, Merger Sub merged with and into Foamix, with Foamix surviving as a wholly-owned subsidiary of Menlo (the “Merger”) on March 9, 2020 (the “Effective Date”).</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For accounting purposes, the Merger is treated as a “reverse acquisition” under generally accepted accounting principles in the United States (“U.S. GAAP”) and Foamix is considered the accounting acquirer. Accordingly, upon consummation of the Merger, the historical financial statements of Foamix became the Company’s historical financial statements, and the historical financial statements of Foamix are included in the comparative prior periods. See “Note 3 – Business Combination” for more information on the Merger.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reverse stock split and recasting of per-share amounts</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 10, 2021, the Company's Board of Directors approved a one-for-four reverse stock split of its outstanding shares of common stock. The reverse stock split was effected on February 12, 2021, at 5:00 p.m. Eastern time. At the effective time, every four issued and outstanding shares of the Company's common stock were converted into one share of common stock. No fractional shares were issued in connection with the reverse stock split, and in lieu thereof, each stockholder holding fractional shares was entitled to receive a cash payment (without interest or deduction) from the Company's transfer agent in an amount equal to such stockholder's respective pro rata shares of the total net proceeds from the Company's transfer agent sale of all fractional shares at the then-prevailing prices on the open market. In connection with the reverse stock split, the number of authorized shares of the Company's common stock was also reduced on a one-for-four basis, from 300 million shares to 75 million shares. The par value of each share of common stock remained unchanged. A proportionate adjustment was also made to the maximum number of shares issuable under the Company's 2019 Equity Incentive Plan, 2018 Omnibus Incentive Plan and 2019 Employee Share Purchase Plan.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless otherwise noted, all common shares and per share amounts contained in the unaudited interim condensed consolidated financial statements have been retroactively adjusted to reflect the reverse stock split.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Topical Minocycline Franchise</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, the Company launched AMZEEQ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a once-daily topical antibiotic for the treatment of inflammatory lesions of non-nodular moderate-to-severe acne vulgaris in patients 9 years of age and older. On May 28, 2020, the U.S. Food and Drug Administration (the "FDA") approved ZILXI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the treatment of inflammatory lesions of rosacea in adults.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ZILXI became available in pharmacies nationwide in October 2020. AMZEEQ and ZILXI are the first topical minocycline products approved by the FDA for any condition.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AMZEEQ and ZILXI utilize the Company’s proprietary Molecule Stabilizing Technology (MST)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">™</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> that is also being used in the development of the Company’s product candidate FCD105, a topical foam comprising minocycline and adapalene for the treatment of acne vulgaris. On June 2, 2020, the Company announced positive results from a Phase II clinical trial evaluating </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the preliminary safety and efficacy of FCD105 (3% minocycline / 0.3% adapalene foam), the first ever topical minocycline-based combination product, for the treatment of moderate-to-severe acne vulgaris.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company held an end-of-Phase II meeting with the FDA in the fourth quarter of 2020. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Serlopitant </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the Company was developing serlopitant, a small molecule inhibitor of the neurokinin 1 receptor, or NK1-R, given as a once-daily, oral tablet, for the treatment of pruritus, or itch, associated with various conditions including prurigo nodularis, or PN. On April 6, 2020, the Company announced top line results from two Phase III clinical trials evaluating the safety and efficacy of once-daily oral serlopitant for the treatment of pruritus (itch) associated with PN, studies MTI-105 and MTI-106. Neither study met their respective primary endpoint of demonstrating statistically significant reduction in pruritus in patients treated with serlopitant compared to placebo based on a 4-point improvement responder analysis. The Company does not currently intend to further pursue the development of serlopitant. As a result, in the second quarter of 2020, the Company recorded a full impairment charge related to the IPR&D and Goodwill assets in its unaudited condensed consolidated statement of operations and comprehensive loss. See "Note 3 - Business Combination" for more information.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company launched AMZEEQ in the United States in January 2020 and commenced generating product revenues in the first quarter of 2020. The Company also launched ZILXI in the United States in October 2020 and commenced generating revenues in the fourth quarter of 2020. The Company’s activities prior to the commercial launches of AMZEEQ and ZILXI had primarily consisted of raising capital, developing product candidates, and performing research and development activities. Since inception, the Company has incurred recurring losses and negative cash flows from operations. For the six months ended June 30, 2021, the Company incurred a net loss of $40.5 million and used $28.8 million of cash in operations. As of June 30, 2021, the Company had cash, cash equivalents, restricted cash and investments of $104.0 million and an accumulated deficit of $606.7 million. The Company's outstanding debt under its Amended and Restated Credit Agreement at June 30, 2021 was $35.0 million. On August 11, 2021, the Company prepaid the entirety of its outstanding indebtedness, including a prepayment premium and accrued but unpaid interest, for a total amount of approximately $36.5 million. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic and government measures taken in response to the pandemic have had a negative impact on the Company's operations. Access to healthcare providers has been limited, which has negatively impacted sales and the Company's ability to execute its commercial strategy with respect to AMZEEQ and ZILXI. In addition, the commercial launches of both AMZEEQ and ZILXI have been negatively impacted by unfavorable payor decisions in March 2021 on product pricing. These conditions have impaired the Company's ability to generate revenue consistent with internal forecasts, which has had a negative impact on its financial condition and liquidity. The Company and its lenders discussed revenue expected to be generated for the trailing twelve month period ended June 30, 2021, the revenue targets included in the Amended and Restated Credit Agreement and the Company’s strategic transition discussed above. Following such discussions, the Company determined to prepay its outstanding indebtedness in addition to a 4% prepayment fee and accrued but unpaid interest in the total amount of approximately $36.5 million on August 11, 2021. Following the prepayment, the Amended and Restated Credit Agreement has been terminated and the security interests thereunder will be terminated. As a result of the above, the Company determined that its projected cash flows from operations, combined with its cash balance after the debt prepayment, would not provide sufficient resources to fund its existing operations, for at least the next twelve months from the issuance of these financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed above, the Company completed a strategic review of its business and has determined to initiate a process to explore a sale or license of its minocycline franchise, including AMZEEQ, ZILXI, FCD105 and the underlying MST platform. The Company will refocus its resources on its immuno-inflammatory pipeline and intends to support the FMX114 and the BETi development programs. Research and development activities for these programs, including preclinical and clinical testing of the Company’s drug candidates, will require significant additional financing. The future viability of the Company is dependent on its ability to successfully pivot to its research and development business strategy and develop commercially viable drug candidates and raise additional capital to finance its operations.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s ability to continue as a going concern is contingent on its ability to sell or license its minocycline franchise, develop future commercially viable products and/or to raise sufficient working capital through either debt or equity financing.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is no assurance the Company will be able to achieve these objectives under acceptable terms or at all.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with Accounting Standards Update (“ASU”) 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (Subtopic 205-40), the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that its unaudited condensed consolidated financial statements are issued. The accompanying condensed </span></div>consolidated financial statements have been prepared assuming that the Company will continue as a going concern and contemplate the realization of assets and the satisfaction of liabilities in the normal course of business. The Company’s ability to continue as a going concern is expected to be impacted by the outcome of the plans outlined above, including the successful sale or license of its minocycline franchise, positive results from clinical trials for FMX114, and the successful development and positive results from clinical trials for the BETi programs. Based on current plans and assumptions, the Company believes that absent sufficient proceeds received from a sale or license of the minocycline franchise, business development transactions or financing transactions, which are all beyond its control, it will not have sufficient cash and cash equivalents to fund its operations beyond one year from the issuance of these financial statements. Accordingly, the Company will, over the course of the next twelve months, require significant additional financing to continue its operations. Each of these factors are subject to uncertainty, and therefore, raise substantial doubt about the Company’s ability to continue as a going concern. Failure to successfully complete a sale or license of the minocycline franchise, develop the noted assets, and receive additional financing will require the Company to delay, scale back or otherwise modify its business and its research and development activities and other operations. The accompanying financial statements do not include any adjustments related to the recoverability and classification of assets or the amounts and classification of liabilities or any other adjustments that might be necessary should the Company be unable to continue as a going concern.
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2021Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
	us-gaap	Net Income Loss NetIncomeLoss	-40500000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-28800000	USD
CY2021Q2	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	104000000.0	USD
CY2021Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-606700000	USD
CY2021Q2	us-gaap	Derivative Number Of Instruments Held DerivativeNumberOfInstrumentsHeld	0	derivativeInstruments
CY2020Q2	us-gaap	Derivative Number Of Instruments Held DerivativeNumberOfInstrumentsHeld	0	derivativeInstruments
CY2020Q2	vyne	Contingent Stock Right Shares Conversion ContingentStockRightSharesConversion	1.2082
CY2020Q2	vyne	Business Combination Effective Exchange Ratio BusinessCombinationEffectiveExchangeRatio	1.8006
CY2020Q2	vyne	Contingent Stock Right Shares Conversion ContingentStockRightSharesConversion	1.2082
CY2020Q2	vyne	Effective Exchange Ratio EffectiveExchangeRatio	1.8006
CY2020Q2	vyne	Shares Issued Upon Conversion Of Common Stock Rights Per Agreement SharesIssuedUponConversionOfCommonStockRightsPerAgreement	74544413	shares
CY2021Q1	vyne	Shares Issued Upon Conversion Of Common Stock Rights Per Agreement SharesIssuedUponConversionOfCommonStockRightsPerAgreement	18636103	shares
CY2020Q1	vyne	Business Combination Acquiree Common Stock Rights Converted To Common Stock BusinessCombinationAcquireeCommonStockRightsConvertedToCommonStock	19600000	USD
CY2020Q2	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	4500000	USD
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	4500000	USD
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2021Q2	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2021Q2	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2020Q2	vyne	Contingent Stock Right Shares Conversion ContingentStockRightSharesConversion	1.2082
CY2020Q2	vyne	Effective Exchange Ratio EffectiveExchangeRatio	1.8006
CY2020Q2	vyne	Shares Issued Upon Conversion Of Common Stock Rights Per Agreement SharesIssuedUponConversionOfCommonStockRightsPerAgreement	74544413	shares
CY2021Q1	vyne	Shares Issued Upon Conversion Of Common Stock Rights Per Agreement SharesIssuedUponConversionOfCommonStockRightsPerAgreement	18636103	shares
CY2020Q2	vyne	Post Merger Parent Ownership By Pre Merger Subsidiary Shareholders PostMergerParentOwnershipByPreMergerSubsidiaryShareholders	0.82
CY2020Q2	vyne	Post Merger Parent Ownership By Pre Merger Parent Stockholders PostMergerParentOwnershipByPreMergerParentStockholders	0.18
CY2020Q2	vyne	Contingent Stock Consideration Remeasurement Gain Loss ContingentStockConsiderationRemeasurementGainLoss	-84700000	USD
CY2020Q2	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	104400000	USD
CY2020Q2	vyne	Shares Issued Upon Conversion Of Common Stock Rights Per Agreement SharesIssuedUponConversionOfCommonStockRightsPerAgreement	74544413	shares
CY2021Q1	vyne	Shares Issued Upon Conversion Of Common Stock Rights Per Agreement SharesIssuedUponConversionOfCommonStockRightsPerAgreement	18636103	shares
CY2020Q2	us-gaap	Share Price SharePrice	1.40
CY2020Q2	us-gaap	Business Combination Pro Forma Information Revenue Of Acquiree Since Acquisition Date Actual BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual	0	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	0	USD
	us-gaap	Business Combination Pro Forma Information Revenue Of Acquiree Since Acquisition Date Actual BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual	0	USD
CY2020Q2	us-gaap	Business Combination Pro Forma Information Earnings Or Loss Of Acquiree Since Acquisition Date Actual BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual	-7594000	USD
	us-gaap	Business Combination Pro Forma Information Earnings Or Loss Of Acquiree Since Acquisition Date Actual BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual	-19637000	USD
CY2020Q2	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	11688000	USD
	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	13438000	USD
CY2020Q2	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	-167441000	USD
	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	-205082000	USD
CY2020Q2	us-gaap	Business Acquisition Pro Forma Earnings Per Share Diluted BusinessAcquisitionProFormaEarningsPerShareDiluted	-1.21
CY2020Q2	us-gaap	Business Acquisition Pro Forma Earnings Per Share Basic BusinessAcquisitionProFormaEarningsPerShareBasic	-1.21
	us-gaap	Business Acquisition Pro Forma Earnings Per Share Diluted BusinessAcquisitionProFormaEarningsPerShareDiluted	-1.23
	us-gaap	Business Acquisition Pro Forma Earnings Per Share Basic BusinessAcquisitionProFormaEarningsPerShareBasic	-1.23
CY2020Q2	vyne	Adjustments To Supplemental Proforma Transaction Costs AdjustmentsToSupplementalProformaTransactionCosts	0	USD
	vyne	Adjustments To Supplemental Proforma Transaction Costs AdjustmentsToSupplementalProformaTransactionCosts	14931000	USD
CY2020Q2	vyne	Adjustments To Supplemental Proforma Acceleration Of Stock Based Compensation AdjustmentsToSupplementalProformaAccelerationOfStockBasedCompensation	0	USD
	vyne	Adjustments To Supplemental Proforma Acceleration Of Stock Based Compensation AdjustmentsToSupplementalProformaAccelerationOfStockBasedCompensation	7199000	USD
CY2020Q2	vyne	Adjustments To Supplemental Proforma Combined Results Of Operations AdjustmentsToSupplementalProformaCombinedResultsOfOperations	0	USD
	vyne	Adjustments To Supplemental Proforma Combined Results Of Operations AdjustmentsToSupplementalProformaCombinedResultsOfOperations	22130000	USD
CY2021Q2	vyne	Revenue Recognition Distribution Trade Discounts And Allowances RevenueRecognitionDistributionTradeDiscountsAndAllowances	16200000	USD
CY2020Q2	vyne	Revenue Recognition Distribution Trade Discounts And Allowances RevenueRecognitionDistributionTradeDiscountsAndAllowances	5900000	USD
	vyne	Revenue Recognition Distribution Trade Discounts And Allowances RevenueRecognitionDistributionTradeDiscountsAndAllowances	31800000	USD
	vyne	Revenue Recognition Distribution Trade Discounts And Allowances RevenueRecognitionDistributionTradeDiscountsAndAllowances	14100000	USD
CY2021Q2	vyne	Estimate Of Product Return Rate Minimum EstimateOfProductReturnRateMinimum	0.02
CY2021Q2	vyne	Estimate Of Product Return Rate Maximum EstimateOfProductReturnRateMaximum	0.03
CY2020Q4	us-gaap	Marketable Securities MarketableSecurities	1027000	USD
CY2021Q2	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	0	USD
	us-gaap	Other Than Temporary Impairment Loss Debt Securities Available For Sale OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale	0	USD
CY2020	us-gaap	Other Than Temporary Impairment Loss Debt Securities Available For Sale OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale	0	USD
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	1000000.0	USD
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	36400000	USD
CY2020Q4	us-gaap	Restricted Investments RestrictedInvestments	0	USD
CY2021Q2	us-gaap	Restricted Investments RestrictedInvestments	0	USD
CY2021Q2	us-gaap	Inventory Write Down InventoryWriteDown	0	USD
CY2020Q2	us-gaap	Inventory Write Down InventoryWriteDown	0	USD
	us-gaap	Inventory Write Down InventoryWriteDown	0	USD
	us-gaap	Inventory Write Down InventoryWriteDown	0	USD
CY2021Q2	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	3466000	USD
CY2021Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2020Q4	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	4042000	USD
CY2021Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	680000	USD
CY2020Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	662000	USD
CY2021Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	4133000	USD
CY2020Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	2700000	USD
CY2021Q2	us-gaap	Inventory Gross InventoryGross	8279000	USD
CY2020Q4	us-gaap	Inventory Gross InventoryGross	7404000	USD
CY2019Q3	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	1100000	USD
CY2021Q2	us-gaap	Interest Expense Debt InterestExpenseDebt	1000000.0	USD
CY2020Q2	us-gaap	Interest Expense Debt InterestExpenseDebt	1000000.0	USD
CY2021Q2	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	100000	USD
CY2020Q2	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	100000	USD
	us-gaap	Interest Expense Debt InterestExpenseDebt	1900000	USD
	us-gaap	Interest Expense Debt InterestExpenseDebt	1900000	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	200000	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	200000	USD
CY2021Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2021Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2019Q1	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	50000000.0	USD
CY2021Q1	vyne	Shares Issued Upon Conversion Of Common Stock Rights Per Agreement SharesIssuedUponConversionOfCommonStockRightsPerAgreement	18636103	shares
	vyne	Share Based Compensation Arrangement By Share Based Payment Award Options And Equity Instruments Other Than Options Grants In Period Total Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodTotalGrantDateFairValue	7500000	USD
	vyne	Share Based Compensation Arrangement By Share Based Payment Award Options And Equity Instruments Other Than Options Grants In Period Total Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodTotalGrantDateFairValue	11400000	USD
CY2020Q2	vyne	Contingent Stock Right Shares Conversion ContingentStockRightSharesConversion	1.2082
CY2020Q2	vyne	Effective Exchange Ratio EffectiveExchangeRatio	1.8006
CY2020Q2	vyne	Contingent Stock Right Shares Conversion ContingentStockRightSharesConversion	1.2082
CY2020Q2	vyne	Effective Exchange Ratio EffectiveExchangeRatio	1.8006
CY2021Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1901000	USD
CY2020Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	10768000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4343000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	12527000	USD
CY2021Q2	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P3Y
CY2021Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	458000	USD
CY2021Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	761000	USD
CY2021Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	151000	USD
CY2021Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1370000	USD
CY2021Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	124000	USD
CY2021Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	1246000	USD
CY2021Q2	vyne	Restricted Investments To Secure Lease Agreements RestrictedInvestmentsToSecureLeaseAgreements	600000	USD

Files In Submission

Name	View Source	Status
0001566044-21-000034-index-headers.html	Edgar Link	pending
0001566044-21-000034-index.html	Edgar Link	pending
0001566044-21-000034.txt	Edgar Link	pending
0001566044-21-000034-xbrl.zip	Edgar Link	pending
ex101zeronda-executiveempl.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
image_0a.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
vyne-20210630.htm	Edgar Link	pending
vyne-20210630.xsd	Edgar Link	pending
vyne-20210630xexx311.htm	Edgar Link	pending
vyne-20210630xexx312.htm	Edgar Link	pending
vyne-20210630xexx321.htm	Edgar Link	pending
vyne-20210630xexx322.htm	Edgar Link	pending
vyne-20210630_cal.xml	Edgar Link	unprocessable
vyne-20210630_def.xml	Edgar Link	unprocessable
vyne-20210630_htm.xml	Edgar Link	completed
vyne-20210630_lab.xml	Edgar Link	unprocessable
vyne-20210630_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$VYNE
VYNE Therapeutics Inc. Stock $vyne

2021 Q2 Form 10-Q Financial Statement

#000156604421000034 Filed on August 12, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VYNE VYNE Therapeutics Inc. Stock $vyne

2021 Q2 Form 10-Q Financial Statement

#000156604421000034 Filed on August 12, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VYNE
VYNE Therapeutics Inc. Stock $vyne